Proceeds will support ongoing clinical evaluation of HepaStem® in ACLF and launch of a clinical trial in late stage NASH set to commence in H1 2019 in Europe with significant further expansion into the US and Asia MONT-SAINT-GUIBERT, Belgium & TOKYO, May 7, 2019-- Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced the closing of a €39.7 million (JPY4.94 billion) Series D financing. The round was co-led by new Japanese investors ITOCHU Corporation, who contributed €10 million to this financing in January, and Shinsei Capital Partners.